Home
AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

Impacting News May 14, 2021

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma

  • Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR 
  • Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85%

AstraZeneca (AZN) and Amgen (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Impacting News
,
May 14, 2021

Other Articles